News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12
TUCSON, Ariz. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on
View HTML
Toggle Summary HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on Breast Cancer Molecular Diagnostics on October 29
TUCSON, Ariz. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) , a diagnostic company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Tuesday, October 29 th in New York City .
View HTML
Toggle Summary HTG Announces the Launch of its New Autoimmune Profiling Assay
TUCSON, Ariz. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be
View HTML
Toggle Summary HTG Molecular Diagnostics, Inc. Provides Update Regarding Companion Diagnostic Development Programs
TUCSON, Ariz. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today provided an update regarding its ongoing efforts related to the development, manufacture and commercialization of
View HTML
Toggle Summary HTG Molecular to Present Corporate Overview at the Cantor 2019 Global Healthcare Conference
TUCSON, Ariz. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that John Lubniewski , President and CEO, will present a corporate overview at the Cantor 2019 Global
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Completion of $22.5 Million Aggregate Financing, Consisting of $19.0 Million Public Offering of Common Stock, Including the Exercise in Full of the Underwriter’s Option to Purchase Additional Shares, and $3.5 Million Co
TUCSON, Ariz. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the completion of its previously announced underwritten public offering of 29,298,537 shares of its common
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Pricing of $20.0 Million Aggregate Financing, Consisting of $16.6 Million Public Offering of Common Stock and $3.5 Million Concurrent Private Placement
TUCSON, Ariz. --(BUSINESS WIRE)--Sep. 20, 2019-- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the pricing of an underwritten public offering of 25,476,989 shares of its common stock at a price to the
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock
TUCSON, Ariz. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an
View HTML
Toggle Summary HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that, on August 15, 2019 the Compensation Committee of its Board of Directors granted inducement stock options
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2019 Results
Product and product-related services revenue increased by 119% and 89%, respectively,  compared to the three and six-month periods in the prior year Call scheduled for today, August 6 , at 4:30pm ET TUCSON, Ariz. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
View HTML